Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Lars D, Engstrom"'
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d677a7e099fb8459d3aaad7bbf29b468
https://doi.org/10.1038/s41591-022-02007-7
https://doi.org/10.1038/s41591-022-02007-7
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Supplementary Composite Figure File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095624453d8ad8530fb345958c4cd8b6
https://doi.org/10.1158/2159-8290.22535530.v1
https://doi.org/10.1158/2159-8290.22535530.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0679ee9794421d5e87ada96097d171a6
https://doi.org/10.1158/1535-7163.c.6543400.v1
https://doi.org/10.1158/1535-7163.c.6543400.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Figures S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ceca5b28312dd8892d9b8d8ba17873c
https://doi.org/10.1158/1535-7163.22522492
https://doi.org/10.1158/1535-7163.22522492
Autor:
James G. Christensen, Tod Smeal, Steven L. Bender, Gerrit Los, Michele McTigue, Jingrong Jean Cui, Sergei Timofeevski, Max Parker, Shinji Yamazaki, Lars D. Engstrom, Ming Qiu, Kristina Burgess, Maria E. Arango, Joseph H. Lee, Qiuhua Li, Helen Y. Zou
PDF file - 44K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6750ad6c98964bf8eae616dbdd3e146e
https://doi.org/10.1158/1535-7163.22498621.v1
https://doi.org/10.1158/1535-7163.22498621.v1
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd866fa6fe03bc0849986ce88d5870c4
https://doi.org/10.1158/2159-8290.c.6547879.v1
https://doi.org/10.1158/2159-8290.c.6547879.v1
Autor:
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc7b96d8807b2e71c6f5c425780ec51
https://doi.org/10.1158/1078-0432.22467627
https://doi.org/10.1158/1078-0432.22467627
Autor:
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom
Supplemental Figure 1. Glesatinib is a potent and selective MET inhibitor. Supplemental Figure 2. Waterfall plot of glesatinib activity across pre-clinical tumor models. Supplemental Figure 3. SNU-638 Criz-res line is homogeneous and harbors the F120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c375882160e71f15fa4df153bf834a2
https://doi.org/10.1158/1078-0432.22467621.v1
https://doi.org/10.1158/1078-0432.22467621.v1
Autor:
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom
Purpose: MET exon 14 deletion (METex14 del) mutations represent a novel class of non–small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a spectrum-selective MET inhibitor exhibiting a type II binding mode, in METex14 del–po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bf6bc9e9872b1b6f95da5a8da32f467
https://doi.org/10.1158/1078-0432.c.6526698.v1
https://doi.org/10.1158/1078-0432.c.6526698.v1
Autor:
Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M. Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J. David Lawson, Krystal Moya, Peter Olson, Lisa Rahbaek, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:1749-1766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6807ba018e034c41898a959b92d453dc
https://doi.org/10.1021/acs.jmedchem.1c01900
https://doi.org/10.1021/acs.jmedchem.1c01900